Concepedia

W. Rachel Duan

WR

Statistics

Publications

18

Citations

2.3K

H-Index

14

Active since

2008

Affiliations

AbbVie (United States)(Current)

KU Leuven

AbbVie (Germany)

Christian-Albrechts-Universität zu Kiel

Amsterdam University Medical Centers

W. Rachel Duan is an author at AbbVie (United States) specializing in pharmacotherapy, pharmacy, and inflammatory bowel disease therapy.

Publications per year

2008–2025

18

Publications

18

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

Hugh S. Taylor, Linda C. Giudice, Bruce A. Lessey et al. · New England Journal of Medicine · 2017 · 493 citations · Full text

, , +17

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 387 citations · Full text

, , +9

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 316 citations · Full text

, , +11

A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia

Lesley M. Arnold, I. Jon Russell, Erdal Diri et al. · Journal of Pain · 2008 · 275 citations

, , +8

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Laurent Peyrin‐Biroulet, J. Casey Chapman, Jean‐Frédéric Colombel et al. · New England Journal of Medicine · 2024 · 160 citations · Full text

, , +13

1–5 of 18